COSMODERMIC
ActiveSummary
COSMODERMIC has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €86,892 and a net result of €23,911. Its solvency ranks better than 53% of 19,751 sector peers (NACE 86, financial year 2024). The computed 12-month bankruptcy probability is 1.0% (low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 02-09-2022 Normal situation
- Registered office
- 23 active companies are registered at this address 2 started in the 12 months before. Source: KBO register, as of 3 November 2026.
- Activity
- Specialist medical practice NACE 86220
- Establishment unit
- 2.339.194.095 1200 Sint-Lambrechts-Woluwe, since 02-09-2022
- Financial year end
- 31 December
- Peppol
- Reachable since 20-02-2026
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.0%
- Gross margin
- €34,999
- ▼ 58.6%
- Turnover
- ≈ €110,000
- estimated
- Profit
- €23,911
- ▼ 62.0%
- Equity
- €86,892
- ▲ 38.0%
- Total assets
- €123,510
- ▲ 51.8%
- 2025 accounts not filed, 95 days past the deadline
Score breakdownraises riskCapped at 59: a confirmed filing finding1 financial year not filed after the legal deadline; last filed accounts filed 425 days late; 2 of the last 3 accounts lateFigures for financial year 2024 (filed on 29-09-2026)lowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 3.20, cash €94,187Show the evidence
Checked score
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 58% of them on solvency, 71% on liquidity, 51% on profitability and 75% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 2 accounts on average 608 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (1)
Financials
Financials · financial year 2024, micro format
2025 annual accounts not yet filed, deadline passed on 31 July 2026 The financial year closed on 31 December 2025. The accounts are due at the latest 7 months after the close (Companies Code art. 3:10). Source: NBB filings, as of 3 November 2026.
Annual accounts 2024 filed on 29-09-2026 at the NBB all 2 filings
Every figure per financial year
The operating result for 2024 is 60% lower than in 2023.
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Investments
| Item | 2023 | 2024 |
|---|---|---|
| Tangible fixed assets | €11,561 | - |
| Depreciation and write-downs of the year | €3,079 | €2,312 |
Source: notes to the 2023 to 2024 annual accounts (statement of fixed assets)
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €3,079 | €2,312 | ▼ 24.9% |
| Other operating charges640/8 | €357 | €0 | ▼ 100% |
| Gross operating margin9900 | €84,531 | €34,999 | ▼ 58.6% |
| Operating profit (loss)9901 | €81,096 | €32,687 | ▼ 59.7% |
| Financial charges65/66B | €46 | €50 | ▲ 9.4% |
| Recurring financial charges65 | €46 | €50 | ▲ 9.4% |
| Profit (loss) for the period before taxes9903 | €81,050 | €32,637 | ▼ 59.7% |
| Income taxes67/77 | €18,068 | €8,726 | ▼ 51.7% |
| Profit (loss) for the period9904 | €62,982 | €23,911 | ▼ 62.0% |
| Profit (loss) for the period to be appropriated9905 | €62,982 | €23,911 | ▼ 62.0% |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Assets | |||
| Total assets20/58 | €81,368 | €123,510 | ▲ 51.8% |
| Fixed assets21/28 | €8,482 | €6,170 | ▼ 27.3% |
| Tangible fixed assets22/27 | €8,482 | €6,170 | ▼ 27.3% |
| Plant, machinery and equipment23 | €8,482 | €6,170 | ▼ 27.3% |
| Current assets29/58 | €72,886 | €117,340 | ▲ 61.0% |
| Amounts receivable within one year40/41 | €2,490 | €153 | ▼ 93.9% |
| Other amounts receivable41 | €2,490 | €153 | ▼ 93.9% |
| Current investments50/53 | €11,000 | €23,000 | ▲ 109% |
| Cash at bank and in hand54/58 | €59,395 | €94,187 | ▲ 58.6% |
| Equity and liabilities | |||
| Total equity and liabilities10/49 | €81,368 | €123,510 | ▲ 51.8% |
| Equity10/15 | €62,982 | €86,892 | ▲ 38.0% |
| Profit (loss) carried forward14 | €62,982 | €86,892 | ▲ 38.0% |
| Amounts payable17/49 | €18,386 | €36,618 | ▲ 99.2% |
| Amounts payable within one year42/48 | €18,386 | €36,618 | ▲ 99.2% |
| Trade debts44 | €318 | €4,478 | ▲ 14× |
| Suppliers440/4 | €318 | €4,478 | ▲ 14× |
| Taxes, remuneration and social security45 | €18,068 | €32,140 | ▲ 77.9% |
| Taxes450/3 | €18,068 | €32,140 | ▲ 77.9% |
| Line | 2023 | 2024 | Change |
|---|---|---|---|
| Profit (loss) for the period9904 | €62,982 | €23,911 | ▼ 62.0% |
| + Depreciation and write-downs630 | €3,079 | €2,312 | ▼ 24.9% |
| Operating cash flow (approximation) | €66,061 | €26,223 | ▼ 60.3% |
| Investment in fixed assets (approximation) | - | €0 | - |
| Change in cash | - | €34,792 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 39,278 companies had the same profile as COSMODERMIC has now. Two years later, 95.8% were still going and 1.8% had gone bankrupt.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of COSMODERMIC itself: 1.0% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for COSMODERMIC. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Board & ownership
Directors
Owners and capital
Shareholders
- JANMOHAMED Sherief Rahit 100 shares (100%) · €3,000 in cash
Capital transactions
- 06-09-2022 Incorporation · €3,000 · 100 shares
Articles of association
Board and representation
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Geboekt op algemene kosten los van representatie-,reis- en verplaatsingskosten, bij bezoldigd bepaalt AV met absolute meerderheid of enige…”
Capital, shares and profit
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Geen beslissing of geen mededeling binnen termijn geldt als geweigerd door alle aandeelhouders, Euribor 12 maanden einde maand weigering…”
Audit, dissolution and liquidation
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one. According to the deed, the legal criteria do not require one here.
- No statutory auditor
Articles of association, deed of 06-09-2022 (in Dutch)
Network & group
COSMODERMIC shares no director with another company.
Companies at the same address
22 other companies- Sidani, Neamat (sole trader) Establishment · since 2026 1030775052
- DBY Consult Registered office · since 2026 1033871332
- BOMMI Registered office · since 2025 1029962826
- Cater, Esteban (sole trader) Establishment · since 2025 1026478249
- Kambe, Hirono (sole trader) Establishment · since 2025 1026092823
- Tamaya, Eddy (sole trader) Establishment · since 2025 1025094812
- HOME INVEST BELGIUM Establishment · since 2024 0420767885
- Ivanova, Neli (sole trader) Establishment · since 2024 1013904772
- BRIGHT STAR LINE Registered office · since 2023 1000966952
- ABG Engineering Establishment · since 2023 0802893744
Connections & network
1 current directorThe network starts from the directors of COSMODERMIC. Every other company they run is a node.
Timeline
Acts, filings and financial milestones
06-09
Gazette deed
IncorporationStarting capital €3,000 · Appointment: JANMOHAMED Sherief Rahit (director) · Founder7 points ▸
- Founder, JANMOHAMED Sherief Rahit (comparant)
- Incorporation, “COSMODERMIC” (deed in Dutch)
- Founding capital, “euro 3.000” (deed in Dutch)
- Capital, “euro 3.000” (deed in Dutch)
- Board rule, 1, “vergadering” (deed in Dutch)
- Director appointment, JANMOHAMED Sherief Rahit (director)
- Other provision, “dag verkrijging rechtspersoonlijkheid, hetzij dag neerlegging ter griffie van uitgifte oprichtingsakte overeenkomstig wet, begin werkzaamheden” (deed in Dutch)
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordRegistered office and establishments
Activities
NACEBEL 2025Codes under NACEBEL 2008
9 activities
- De uitoefening van de geneeskunde met specialisatie dermatologie en venerologie door de artsaandeelhouder,met inachtneming van de regels van de medische deontologie.
- De aandeelhouder oefent zijn volledige medische activiteit uit in naam en voor rekening van de vennootschap.
- De professionele aansprakelijkheid van de artsaandeelhouder is onbeperkt.
- Deze activiteiten worden uitgeoefend met eerbiediging van de deontologische en administratieve voorschriften,volgens de principes van de medische ethiek en de eisen van de wetenschappelijke discipline.
- Meer bepaald zal de vrije artsenkeuze in hoofde van de patiënt,de diagnostische en therapeutische vrijheid alsook het respect voor het medisch beroepsgeheim behouden blijven.
- De vennootschap waakt erover dat de onafhankelijkheid van de aandeelhouder in de uitoefening van zijn beroep gewaarborgd blijft en dat geen aanleiding ontstaat tot commerciële beoefening van de geneeskunde,tot directe of indirecte collusie,dichotomie of overconsumptie,volgens de medische plichtenleer en onder de specifieke beroepsaansprakelijkheid van de vennoten,zoals bepaald door de raad van de Orde van Artsen.
- De arts die een patiënt behandelt,zal bijgevolg tegenover deze laatste,als arts persoonlijk aansprakelijk blijven.
- De arts dient verzekerd te zijn voor zijn medische fouten.
- De aansprakelijkheid van de vennootschap dient gewaarborgd te zijn.
Invoicing and payment
Financial year and general meeting
Accounts at the NBBSites & property
Buildings and parcels at the address
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 21018A0008/00N000 | Brussels | 3,920 m² | 1 · 1,596 m² | 33.8 m · 10 |